Shots:

• The P-Ib/II CARTITUDE-1 study involves assessing JNJ-4528 in 29 heavily pretreated patients with r/r MM. The P-Ib results will be shared at ASCO
• The P-Ib/II study results: 100% ORR with 97% good PR and 3% PR; patients achieving stringent CR @median of 11.5mos (86%)- PFS at 9mos (86%); median time to first response was 1mos. and 81% patients achieved MRD negative disease status at 10-⁵ or 10-⁶
• JNJ-4528 (LCAR-B38M) is CAR-T cell therapy with two BCMA-targeting single domain Abs and has received EMA’s PRIME designation in Apr’2019 and ODD in Feb’2020. Additionally- in 2017- Janssen collaborated with Legend Biotech to develop and commercialize JNJ-452 while in May’2018- Janssen initiated the P-Ib/II study to assess JNJ-4528- informed by the LEGEND-2 study results

Click here ­to­ read full press release/ article 

Ref: Businesswire | Image: Janssen